Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Stem Cell Research

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 52 articles:
HTML format
Text format



Single Articles


    September 2017
  1. ARBOE B, Halgren Olsen M, Duun-Henriksen AK, Gorlov JS, et al
    Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2017 Sep 4:1-10. doi: 10.1080/10428194.2017.1369061.
    PubMed     Text format     Abstract available


    August 2017
  2. WINTER A, Rybicki L, Shah SN, Jagadeesh D, et al
    Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2017 Aug 30:1-7. doi: 10.1080/10428194.2017.1369065.
    PubMed     Text format     Abstract available


  3. DHERE V, Edelman S, Waller EK, Langston A, et al
    Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Aug 7:1-7. doi: 10.1080/10428194.2017.1361027.
    PubMed     Text format     Abstract available


    July 2017
  4. SANTIAGO V, Lazaryan A, McClune B, McKenna RW, et al
    Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome.
    Leuk Lymphoma. 2017 Jul 21:1-9. doi: 10.1080/10428194.2017.1352094.
    PubMed     Text format     Abstract available


  5. SIMONETTA F, Masouridi-Levrat S, Beauverd Y, Tsopra O, et al
    Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2017 Jul 6:1-11. doi: 10.1080/10428194.2017.1344844.
    PubMed     Text format     Abstract available


  6. HAMPRAS SS, Locke FL, Chavez JC, Patel NS, et al
    Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients.
    Leuk Lymphoma. 2017 Jul 6:1-7. doi: 10.1080/10428194.2017.1342822.
    PubMed     Text format     Abstract available


    June 2017
  7. NASILLO V, Paolini A, Riva G, Morselli M, et al
    Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2017 Jun 7:1-4. doi: 10.1080/10428194.2017.1321748.
    PubMed     Text format    


  8. MICHALLET M, Sobh M, Garban F, Bulabois CE, et al
    Extracorporeal photopheresis for GVHD prophylaxis after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation: a prospective multicenter phase 2 study.
    Leuk Lymphoma. 2017 Jun 7:1-9. doi: 10.1080/10428194.2017.1334120.
    PubMed     Text format     Abstract available


  9. GAUTAM A, Zhu Y, Ma E, Lee SY, et al
    Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
    Leuk Lymphoma. 2017 Jun 5:1-8. doi: 10.1080/10428194.2017.1324160.
    PubMed     Text format     Abstract available


  10. LI Z, Wang Y, Wang J, Zhang J, et al
    Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2017 Jun 2:1-8. doi: 10.1080/10428194.2017.1330467.
    PubMed     Text format     Abstract available


  11. MILONE G, Martino M, Leotta S, Spadaro A, et al
    Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.
    Leuk Lymphoma. 2017 Jun 2:1-7. doi: 10.1080/10428194.2017.1324161.
    PubMed     Text format     Abstract available


  12. HAZAR V, Kesik V, Karasu GT, Ozturk G, et al
    Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry.
    Leuk Lymphoma. 2017 Jun 2:1-12. doi: 10.1080/10428194.2017.1330472.
    PubMed     Text format     Abstract available


    May 2017
  13. XIAO X, Huang H, Chen J, Jiang Y, et al
    Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 16:1-5. doi: 10.1080/10428194.2017.1317096.
    PubMed     Text format    


  14. SKAMENE T, Crump M, Savage KJ, Reiman T, et al
    Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
    Leuk Lymphoma. 2017 May 15:1-9. doi: 10.1080/10428194.2017.1312379.
    PubMed     Text format     Abstract available


  15. DEBUS L, Vigouroux S, Gargallo G, Adiko F, et al
    No adverse effect of granulocyte colony-stimulating factor during the peri-implantation period of an unrecognized pregnancy in a donor of peripheral blood stem cells.
    Leuk Lymphoma. 2017 May 9:1-2. doi: 10.1080/10428194.2017.1312389.
    PubMed     Text format    


    March 2017
  16. EL CHEIKH J, Massoud R, Haffar B, Fares E, et al
    Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307362.
    PubMed     Text format    


  17. ANGUITA-COMPAGNON AT, Dibarrart MT, Paredes L, Araos D, et al
    Peripheral blood stem cell mobilization with a single dose of PEG-filgrastim in patients with multiple myeloma previously treated with radiotherapy.
    Leuk Lymphoma. 2017 Mar 16:1-4. doi: 10.1080/10428194.2017.1300895.
    PubMed     Text format    


  18. COCITO F, Mangiacavalli S, Bernasconi P, Colombo AA, et al
    Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report.
    Leuk Lymphoma. 2017 Mar 13:1-2. doi: 10.1080/10428194.2017.1300890.
    PubMed     Text format    


    February 2017
  19. NICOL C, Henry C, Couturier MA, Delepine P, et al
    Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only.
    Leuk Lymphoma. 2017 Feb 7:1-3. doi: 10.1080/10428194.2017.1285025.
    PubMed     Text format    


    January 2017
  20. GREIL C, Kiote-Schmidt C, Fink G, Ihorst G, et al
    Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.
    Leuk Lymphoma. 2017 Jan 13:1-13. doi: 10.1080/10428194.2016.1271946.
    PubMed     Text format     Abstract available


    December 2016
  21. HOGAN JJ, Loren AW, Denker MG, Mangan JK, et al
    Edema with hypoalbuminemia as a rare manifestation of chronic graft versus host disease after allogeneic hematopoietic cell transplant.
    Leuk Lymphoma. 2016 Dec 21:1-3. doi: 10.1080/10428194.2016.1270451.
    PubMed     Text format    


    November 2016
  22. SHINOHARA A, Inamoto Y, Kurosawa S, Hiramoto N, et al
    High non-relapse mortality and low relapse incidence in gender-mismatched allogeneic hematopoietic stem cell transplantation from a parous female donor with a male child.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  23. CHOE H, Martin P
    Frontline autologous stem cell transplant for high-risk follicular lymphoma: forever elusive?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    October 2016
  24. PHILLIPS AA
    Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  25. STETTLER J, Novak U, Baerlocher GM, Seipel K, et al
    Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  26. OGUNNIYI A, Rodriguez M, Devlin S, Adel N, et al
    Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  27. WANG W, Foerner E, Buss E, Jauch A, et al
    Hematopoietic stem cells can be separated from leukemic cells in a subgroup of adult acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  28. ZHAO XS, Qin YZ, Liu YR, Chang YJ, et al
    The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    September 2016
  29. GUPTA R, Kumar L, Dahiya M, Mathur N, et al
    Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  30. TOKUNAGA M, Uto H, Takeuchi S, Nakano N, et al
    Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    August 2016
  31. SORIGUE M, Sancho JM, Morgades M, Moreno M, et al
    Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  32. SHARMA P, Shinde SS, Damlaj M, Hefazi Rorghabeh M, et al
    Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  33. KOLDEHOFF M, Ross SR, Duhrsen U, Beelen DW, et al
    Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  34. ASLAN A, Aras T, Ozdemir E
    Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  35. MONTORO J, Sanz J, Sanz GF, Sanz MA, et al
    Advances in haploidentical stem cell transplantation for hematologic malignancies.
    Leuk Lymphoma. 2016;57:1766-75.
    PubMed     Text format     Abstract available


    July 2016
  36. BALASSA K, Krahling T, Remenyi P, Batai A, et al
    Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    June 2016
  37. BRAMMER JE, Khouri I, Marin D, Ledesma C, et al
    Stem cell transplantation outcomes in lymphoblastic lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  38. MAYER S, Pastores SM, Riedel E, Maloy M, et al
    Short- and long-term outcomes of adult allogeneic hematopoietic stem cell transplant patients admitted to the intensive care unit in the peritransplant period.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  39. BEAUVERD Y, Cortes B, Masouye I, Chalandon Y, et al
    Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  40. BAETZ T, Chen BE, Couban S, Tom Kouroukis C, et al
    Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    May 2016
  41. SHIPOUNOVA IN, Petinati NA, Bigildeev AE, Drize NJ, et al
    Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  42. ISIDORI A, Christofides A, Visani G
    Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  43. MICHALLET M, Sobh M, Labussiere H, Lombard C, et al
    Potential anti-leukemic activity of iron chelation after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  44. FIALA MA, Slade M, Wang S, Park S, et al
    The impact of diabetes mellitus and other comorbidities on hematopoietic stem cell collection and hematologic recovery post-transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  45. THOMAS CM, Ippoliti C, Roboz GJ, Feldman E, et al
    Clofarabine as a bridge to hematopoietic stem cell transplant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  46. ITONAGA H, Taguchi J, Taguchi M, Taniguchi H, et al
    Adult T-cell leukemia/lymphoma in donor cells responding to second allogeneic hematopoietic stem cell transplantation using unrelated cord blood: the Nagasaki Transplant Group experience.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  47. CHIEW MY, Boo NY, Voon K, Cheong SK, et al
    Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  48. GRAIN A, Sirvent A, Strullu M, Francoise M, et al
    Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bo
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  49. VON TRESCKOW B, Morschhauser F, Szer J, Eichenauer DA, et al
    Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    August 2015
  50. FUNGPIPAT P, Sophonphan J, Sosothikul D, Suppipat K, et al
    Redefine Clinical Risk Classification in Children with Precursor B Cell Acute Lymphoblastic Leukemia using Pretreatment Absolute Lymphocyte Count.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  51. ILIFF A, Divine C, Diaz F, Aljitawi O, et al
    Adequacy of Peripheral Blood Stem Cell Mobilization in Patients with Relapsed B Cell Non Hodgkin Lymphoma Treated with Bendamustine.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


    March 2015
  52. KOLDEHOFF M, Lindemann M, Opalka B, Bauer S, et al
    Cytomegalovirus induces apoptosis in acute leukemia cells as a virus-versus-leukemia function.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stem Cell Research is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: